Trinity Biotech Promotes John Gillard, its CFO, To President And CEO, Effective Immediately; Des Fitzgerald Named As Interim CFO
Portfolio Pulse from Benzinga Newsdesk
Trinity Biotech has announced the immediate promotion of its CFO, John Gillard, to President and CEO. Aris Kekedjian has resigned from his role as CEO and from the Trinity Board of Directors effective December 17, 2023. Des Fitzgerald has been named as the Interim CFO.
December 18, 2023 | 9:34 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
John Gillard has been promoted to President and CEO of Trinity Biotech, with Des Fitzgerald stepping in as Interim CFO after Aris Kekedjian's resignation.
Executive changes can lead to shifts in company strategy and investor confidence. However, as the changes are internal promotions, the immediate impact on stock price may be neutral. Investors will likely adopt a 'wait and see' approach to assess the new leadership's impact on the company's performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100